Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
173 hedge funds and large institutions have $721M invested in Avadel Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 51 reducing their positions, and 28 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 51
18% more capital invested
Capital invested by funds: $613M → $721M (+$108M)
3.62% more ownership
Funds ownership: 80.58% → 84.2% (+3.6%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 28
1% less funds holding
Funds holding: 175 → 173 (-2)
38% less call options, than puts
Call options by funds: $2.43M | Put options by funds: $3.91M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
| 2 |
BlackRock
New York
|
+$11.9M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$10.6M |
| 4 |
TLP
Tri Locum Partners
New York
|
+$8.91M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$21.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$8.56M |
| 3 |
GJL
Gendell Jeffrey L
|
-$8.35M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.68M |
AVDL Hedge Fund Activity: Q2 2025 in Review
173 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2025, worth a combined $721M — up 18% from $613M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of AVDL and 27 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 69 added.
The largest buyer was Vanguard Group, adding an estimated $14.6M. The largest seller was Janus Henderson Group, cutting an estimated $21.6M.
- 173 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2025, down from 175 in Q1 2025.
- Funds reported $721M of Avadel Pharmaceuticals stock for Q2 2025, up 18% quarter-over-quarter.
- 27 funds opened new Avadel Pharmaceuticals positions in Q2 2025 and 28 closed out, a net change of -1 holder.
- The largest Avadel Pharmaceuticals buyer in Q2 2025 was Vanguard Group, an estimated $14.6M added.
- The largest Avadel Pharmaceuticals seller in Q2 2025 was Janus Henderson Group, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2025.